Sodium Oxybate: A Review of Its Use in Alcohol Withdrawal Syndrome and in the Maintenance of Abstinence in Alcohol Dependence

@article{Keating2013SodiumOA,
  title={Sodium Oxybate: A Review of Its Use in Alcohol Withdrawal Syndrome and in the Maintenance of Abstinence in Alcohol Dependence},
  author={Gillian M. Keating},
  journal={Clinical Drug Investigation},
  year={2013},
  volume={34},
  pages={63-80}
}
  • G. Keating
  • Published 2013
  • Medicine
  • Clinical Drug Investigation
A liquid formulation of sodium oxybate (Alcover®), the sodium salt of γ-hydroxybutyric acid (GHB), is approved in Italy and Austria for use in alcohol withdrawal syndrome and for the maintenance of abstinence in alcohol dependence. This article reviews the efficacy and tolerability of sodium oxybate in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence, as well as summarizing its pharmacological properties. Results of randomized controlled trials indicate… 

A Brief Up-Date of the Use of Sodium Oxybate for the Treatment of Alcohol Use Disorder

The aim of the present review is to examine the role of SMO in the treatment of AUD, its possible implications in reducing alcohol consumption, and cases of abuse, and severe intoxication due to SMO during its clinical use in the Treatment of AUD.

Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial

A large RCT in alcohol-dependent patients demonstrated a significant and clinically relevant sustained effect of SMO on CAD and the SMO effect was sustained during the medication-free follow-up period.

Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series

It is shown that, during the first month of the combined treatment of sodium oxybate plus nalmefene, patients were able to achieve alcohol abstinence, to suppress or reduce episodes of heavy drinking days, and to suppress the onset of craving for sodium oxyBate.

Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome.

The effectiveness of sodium oxybate therapy for the treatment of alcohol withdrawal syndrome (AWS) and the maintenance of alcohol abstinence has been assessed and some randomized data suggest that GHB is better than naltrexone and disulfiram regarding abstinence maintenance and prevention of craving in the medium term i.e. 3-12 months.

Management of patients with alcohol withdrawal syndrome

The evidence base for appropriate clinical management of the alcohol withdrawal syndrome is reviewed and Symptom triggered regime is favoured over fixed tapering dose regime, although monitoring through scales is cumbersome.

Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond.

The evidence base for appropriate clinical management of the alcohol withdrawal syndrome is reviewed and Symptom triggered regime is favoured over fixed tapering dose regime, although monitoring through scales is cumbersome.

The recognition and management of protracted alcohol withdrawal may improve and modulate the pharmacological treatment of alcohol use disorder

Protracted alcohol withdrawal (PAW), an underestimated and not yet clearly defined clinical condition that follows the acute stage of AWS, is characterized by the presence of substance-specific signs and symptoms common to acute AWS, but persisting beyond the generally expected acute AWS time frames.

Inpatient Management of Acute Alcohol Withdrawal Syndrome

Alcohol withdrawal is a common condition encountered in the hospital setting after abrupt discontinuation of alcohol in an alcohol-dependent individual and management revolves around early identification of at-risk individuals and symptom assessment using a validated tool such as the revised Clinical Institute Withdrawal Assessment for Alcohol score.

Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol

A task force of specialists drew up recommendations for the treatment of alcohol withdrawal syndrome with the following main results: while mild AWS may not require treatment, moderate and severe AWS need to be pharmacologically treated.
...

References

SHOWING 1-10 OF 77 REFERENCES

Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity

Sodium oxybate in maintaining alcohol abstinence in alcoholic patients according to Lesch typologies: A pilot study

The results confirm that alcoholics with psychiatric co-morbidity, particularly with a borderline personality disorder of Axis II, are at a greater risk of developing craving for and abuse of the drug: until craving for alcohol and craving for SO are characterized in depth, SO should be used with caution in these patients.

New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications

Substitution therapy for alcoholism: time for a reappraisal?

The time now seems right for reappraising the use of substitute prescribing for alcohol dependence, where existing therapies are only effective in a proportion of patients, and which has high morbidity and mortality.

Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine.

BACKGROUND Benzodiazepine has been shown to be one of the most effective class of drugs in the management of alcohol withdrawal syndrome (AWS). Gamma-hydroxybutyric acid (GHB) has recently been

Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study.

Gamma-Hydroxybutyric Acid versus Clomethiazole for the Treatment of Alcohol Withdrawal Syndrome in a Medical Intensive Care Unit: An Open, Single-Center Randomized Study

Background: Clomethiazole (CLO) has been shown to be effective in treating alcohol withdrawal syndrome (AWS). Gamma-Hydroxybutyric acid (GHB) has also been introduced in the treatment of alcoholic

Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses.

GHB 50mg is effective compared to placebo in the treatment of AWS, and in preventing relapses in previously detoxified alcoholics at 3 months follow-up, but the results of this review do not provide sufficient evidence in favour of GHB compared to benzodiazepines and Chlormethiazole for AWS prevention.

gamma-Hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study.

The effect of gamma-hydroxybutyric acid on alcohol consumption and alcohol craving in alcoholics was investigated in a randomized double-blind study versus placebo. Patients were treated as
...